Clinical

Dataset Information

0

TR accompanied with the study titled A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H).


ABSTRACT: Primary outcome(s): 1. Evaluation of genome abnormality and gene expression by omics analysis of tumor etc. 2. TCR repertoire analysis and RNA expression analysis etc. of T cells in tumor tissue and peripheral blood. 3. Prediction and identification of tumor neo-antigen and evaluation of immunogenicity etc. 4. Analyze ctDNA(16S rRNA PCR) and feces of patients with advanced solid malignancies over time to profile and monitor cancer-related genomic alterations 5. Assessment of the relationship between the analysis above and clinical pathological features or therapeutic efficacy etc.

DISEASE(S): Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Biliary Tract Cancer, Pancreatic Cancer, And Other Solid Cancer

PROVIDER: 2648665 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 105717 | ecrin-mdr-crc
| 2332627 | ecrin-mdr-crc
| 26030 | ecrin-mdr-crc
2021-10-15 | E-MTAB-9686 | biostudies-arrayexpress
2005-11-05 | GSE3525 | GEO
2024-07-15 | PXD051404 | Pride
2023-06-14 | GSE212891 | GEO
2019-03-20 | MSV000083601 | GNPS
2024-08-01 | GSE242929 | GEO
2013-03-01 | E-GEOD-44752 | biostudies-arrayexpress